Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Janssen-Cilag International NV
🇧🇪
Belgium
Country
🇧🇪
Belgium
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
Phase 4
Completed
Conditions
Psoriasis
Interventions
Drug: Ustekinumab
Drug: Methotrexate
Subscribe
First Posted Date
2010-02-01
Last Posted Date
2014-11-24
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
490
Registration Number
NCT01059773
Subscribe
InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
Completed
Conditions
Schizophrenia
Interventions
Drug: Risperidone Long-Acting injectable or oral antipsychotics
Subscribe
First Posted Date
2009-12-04
Last Posted Date
2013-06-24
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
1085
Registration Number
NCT01026285
Subscribe
A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously
Phase 4
Completed
Conditions
Pain
Analgesia, Patient-Controlled
Pain, Postoperative
Interventions
Drug: IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
Drug: IV Morphine Patient-Controlled Analgesia (IV PCA)
Subscribe
First Posted Date
2009-10-16
Last Posted Date
2014-01-29
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
657
Registration Number
NCT00996177
Subscribe
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
Phase 3
Completed
Conditions
Pain
Osteoarthritis, Hip
Osteoarthritis, Knee
Interventions
Drug: Placebo
Drug: OROS hydromorphone HCl
Subscribe
First Posted Date
2009-09-21
Last Posted Date
2014-04-25
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
288
Registration Number
NCT00980798
Subscribe
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Lenalidomide
Subscribe
First Posted Date
2009-05-25
Last Posted Date
2015-01-15
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
163
Registration Number
NCT00908232
Subscribe
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Phase 2
Completed
Conditions
HIV Infection
HIV
Acquired Immunodeficiency Syndrome
Interventions
Drug: etravirine (ETR, TMC125)
Drug: efavirenz (EFV)
Subscribe
First Posted Date
2009-05-18
Last Posted Date
2013-01-14
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
157
Registration Number
NCT00903682
Subscribe
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
Phase 3
Completed
Conditions
Attention Deficit/ Hyperactivity Disorder
Interventions
Drug: prolonged release (PR) OROS methylphenidate 72 mg
Drug: Placebo
Drug: prolonged release (PR) OROS methylphenidate 54 mg
Subscribe
First Posted Date
2008-07-14
Last Posted Date
2014-05-08
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
279
Registration Number
NCT00714688
Subscribe
Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics
Completed
Conditions
Schizophrenia
Subscribe
First Posted Date
2008-06-13
Last Posted Date
2013-02-05
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
3064
Registration Number
NCT00696813
Subscribe
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: paliperidone ER
Drug: olanzapine
Subscribe
First Posted Date
2008-03-27
Last Posted Date
2014-05-08
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
462
Registration Number
NCT00645099
Subscribe
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Paliperidone
Subscribe
First Posted Date
2007-12-03
Last Posted Date
2013-08-02
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
294
Registration Number
NCT00566631
Subscribe
Prev
1
2
3
4
5
6
7
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy